Aceclidine Presbyopia Eye Drop

A New Chapter in Vision Support

Blurry near vision — known medically as presbyopia — affects millions of adults worldwide as the eye’s ability to focus up close naturally declines with age. For decades, options were limited to glasses, contact lenses, or surgery, with no drug-based solution that reliably restored near focus. That changed during 2024–2025 with the development and approval of a new type of therapeutic eye drop.

The Aceclidine presbyopia eye drop — formerly known as LNZ100 and now marketed under the brand name VIZZ — represents a new pharmacological approach to improving near vision without invasive procedures. It works by carefully constricting the pupil to increase the eye’s depth of field, enabling sharper focus at close range.

This innovation reflects a broader shift in ophthalmology toward nonsurgical, pharmacological vision correction — a field that saw significant attention in 2024 and culminated in regulatory milestones in 2025.

What This Innovation Entails

Rather than relying on lenses or surgical alteration, the aceclidine eye drop delivers a targeted biochemical effect on the eye’s pupil mechanism. The active ingredient, aceclidine, acts as a pupil-constricting agent that enhances the eye’s optical properties for near focus. Its effect can last several hours after a single daily application.

Unlike older approaches that only managed visual symptoms, this therapy employs a pharmacological mechanism that directly influences visual performance:

• Aceclidine as a miotic agent — creates a “pinhole” effect that enhances depth of focus.
• Once-daily application — designed for convenience and steady improvement of near vision.
• Preservative-free formulation — single-use vials reduce contamination risk.

This combination of biochemical action and user-centered design positions it differently from both traditional lens-based solutions and older miotic drugs.

Timeline of Innovation (2024–2025)

The path from concept to commercial availability unfolded over a multi-year clinical and regulatory process:

• 2024: Positive Phase 3 clinical data were reported, demonstrating significant improvement in near vision without compromising distance vision.
• October 2024: The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for LNZ100.
• August 8, 2025: Target date for FDA decision under the Prescription Drug User Fee Act (PDUFA).
• July 31, 2025: FDA approval of VIZZ (aceclidine 1.44%), making it the first and only aceclidine-based eye drop indicated for presbyopia.
• October 2025: Commercial launch of VIZZ in the United States, marking real-world availability.

These milestones reflect a concentrated innovation cycle culminating in regulatory approval and product launch — a rare outcome in pharmaceutical development within such a short window. 

Why This Matters

Historically, presbyopia was treated with external aids like reading glasses, which only mask the symptom without altering the eye’s optical behavior. The approval of VIZZ introduces a nonsurgical, pharmacological option that can improve near vision without daily reliance on corrective lenses or invasive procedures.

This matters for several reasons:

• Accessibility: A simple eye drop can be used at home without medical procedures.
• Quality of life: Adults with presbyopia may experience improved near vision with minimal lifestyle disruption.
• Medical innovation: It broadens the therapeutic landscape beyond lenses and surgery to pharmacological correction.

The broader trend reflects how vision care is evolving, with innovative drug therapies joining traditional ophthalmic approaches.

Real-World Impact

Presbyopia affects an estimated 1.8 billion people globally and about 128 million adults in the United States alone. The availability of a once-daily therapeutic eye drop expands choice and may reduce dependence on optical devices for many patients.

For users approaching or past middle age, this means potentially clearer near vision without frequent lens changes, adding convenience and improving functional vision in daily tasks like reading, cooking, and digital screen use.